A new co-operative group: the European Myeloma Network Trialist Group DOI: 10.1080/10428190903191874 Publication date: October 2009 Read More
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) Main author: Bringhen DOI: 10.3324/haematol.2018.191288 Publication date: September 2018 Read More
European Myeloma Network guidelines for the management of multiple myeloma-related complications Main author: Terpos DOI: 10.3324/haematol.2014.117176 Publication date: January 2015 Read More
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias Main author: Gavriatopoulou DOI: 10.1038/s41375-018-0209-7 Publication date: September 2018 Read More
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma Main author: Engelhardt DOI: 10.3324/haematol.2013.099358 Publication date: January 2014 Read More
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when Main author: Caers DOI: 10.3324/haematol.2018.189159 Publication date: November 2018 Read More
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Main author: Engelhardt DOI: 10.3109/10428194.2010.516378 Publication date: January 2010 Read More
European myeloma network: the value of collaborative research Main author: Sonneveld DOI: 10.1159/000087039 Publication date: January 2005 Read More
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives Main author: Gay DOI: 10.3324/haematol.2017.174573 Publication date: February 2018 Read More
Insights on Multiple Myeloma Treatment Strategies Main author: Mateos DOI: 10.1097/HS9.0000000000000163 Publication date: December 2018 Read More
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study Main author: Bringhen DOI: 10.1038/s41375-018-0024-1 Publication date: January 2018 Connected Trials: EMN07 Read More
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement Main author: Dimopoulos DOI: 10.1038/leu.2011.3. Publication date: January 2011 Read More
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) Main author: Larocca DOI: 10.1038/s41375-018-0142-9 Publication date: January 2018 Read More
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) Main author: Palumbo DOI: 10.1182/blood-2011-06-358812 Publication date: January 2011 Read More
Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Main author: Sonneveld DOI: 10.1182/blood-2014-05-576256. Publication date: January 2015 Read More
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network Main author: Ludwig DOI: 10.1038/leu.2017.353 Publication date: January 2017 Read More
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network Main author: Ludwig DOI: 10.1038/s41375-018-0040-1 Publication date: January 2018 Read More
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN) Main author: Dimopoulos DOI: 10.1182/blood-2013-05-503862 Publication date: January 2013 Read More
Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Main author: Dimopoulos DOI: 10.1182/blood-2013-05-503862. Publication date: January 2013 Read More
Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders Main author: Ross DOI: 10.3324/haematol.2011.056176 Publication date: February 2012 Read More
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders Main author: Rawstron DOI: 10.3324/haematol.11080 Publication date: January 2008 Read More
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network Main author: Ozaki DOI: 10.1159/000357394 Publication date: January 2014 Read More
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Main author: Fayers DOI: 10.1182/blood-2011-03-341669. Publication date: January 2011 Read More
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network Main author: van de Donk DOI: 10.3324/haematol.2013.100552 Publication date: July 2014 Read More
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Main author: Terpos DOI: 10.1093/annonc/mdn796 Publication date: January 2009 Read More